0
Signin
countryflagUS

18889881171

AAPL 182.74 0.1864% MSFT 410.54 0.2932% GOOG 171.16 -1.0521% GOOGL 169.38 -1.092% AMZN 188.0 -0.4026% NVDA 904.12 -0.1568% META 472.6 0.9311% TSLA 174.72 -1.7378% TSM 143.6 1.7646% LLY 775.0 -0.3561% V 277.19 0.2641% AVGO 1325.37 1.7082% JPM 195.65 2.0339% UNH 503.21 0.4491% NVO 126.69 -0.4714% WMT 60.3 -0.5279% LVMUY 169.84 -0.2174% XOM 116.15 -0.0172% LVMHF 846.814 -0.7252% MA 454.77 0.3774%

Biogen Inc

Healthcare US BIIB

219.72USD
0.80(0.37%)

Last update at 2024-05-08T20:06:00Z

Day Range

217.00221.53
LowHigh

52 Week Range

220.86319.76
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 3591.80M 1745.20M 5047.50M 7125.90M 5899.60M
Minority interest 85.30M 171.50M 59.90M -4.10000M 43.30M
Net income 3046.90M 1556.10M 4000.60M 5888.50M 4430.70M
Selling general administrative 2403.60M 2623.60M 2504.00M 2374.70M 2106.30M
Selling and marketing expenses - - - - -
Gross profit 7895.10M 8872.00M 11639.40M 12422.50M 11636.60M
Reconciled depreciation 365.90M 487.70M 457.20M 680.60M 1016.60M
Ebit 2320.20M 2840.70M 4550.10M 7042.60M 6113.00M
Ebitda 2686.10M 3656.60M 4807.30M 7518.70M 6860.30M
Depreciation and amortization 365.90M 815.90M 257.20M 476.10M 747.30M
Non operating income net other 614.50M -1060.60000M 502.70M 3.90M 11.00M
Operating income 2320.20M 2840.70M 4550.10M 7042.60M 5888.60M
Other operating expenses 7271.50M 8173.70M 8998.30M 7342.20M 7452.10M
Interest expense 246.60M 253.60M 222.50M 187.40M 200.60M
Tax provision 632.80M 52.50M 992.30M 1158.00M 1425.60M
Interest income 89.30M 11.00M 42.00M 120.00M 112.50M
Net interest income -157.30000M -242.60000M -180.50000M -67.40000M -88.10000M
Extraordinary items - - - - -23.70000M
Non recurring 131.10M 18.00M 75.00M 1.50M 124.50M
Other items - - - - -
Income tax expense 632.80M 52.50M 992.30M 1158.00M 1425.60M
Total revenue 10173.40M 10981.70M 13444.60M 14377.90M 13452.90M
Total operating expenses 4993.20M 6064.00M 7193.10M 5386.80M 5635.80M
Cost of revenue 2278.30M 2109.70M 1805.20M 1955.40M 1816.30M
Total other income expense net 1271.60M -1095.50000M 497.40M 83.30M -101.20000M
Discontinued operations - - - - -
Net income from continuing ops 2961.60M 1692.70M 4055.20M 5967.90M 4474.00M
Net income applicable to common shares 3046.90M 1556.10M 4000.60M 5888.50M 4430.70M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 24554.10M 23877.30M 24618.90M 27234.30M 25288.90M
Intangible assets 1850.10M 2221.30M 3084.30M 3527.40M 3120.00M
Earning assets - - - - -
Other current assets 1417.60M 1153.10M 1294.60M 1221.20M 1214.50M
Total liab 11165.70M 12917.60M 13932.80M 13895.20M 12257.30M
Total stockholder equity 13388.40M 10959.70M 10686.10M 13339.10M 13031.60M
Deferred long term liab 334.70M 694.50M 1032.80M 2810.80M 1636.20M
Other current liab 2781.30M 3299.10M 3287.30M 3368.00M 2924.70M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 16466.50M 13911.70M 13976.30M 16455.40M 16257.00M
Other liab 1278.90M 2015.00M 2362.40M 4159.70M 3025.60M
Good will 5749.00M 5761.10M 5762.10M 5757.80M 5706.40M
Other assets 1652.90M 3354.60M 4196.00M 3232.10M 2160.50M
Cash 3419.30M 2261.40M 1331.20M 2913.70M 1224.60M
Cash and equivalents - - - - -
Total current liabilities 3272.80M 4298.20M 3742.20M 4863.80M 3295.20M
Current deferred revenue - -589.20000M - -530.80000M -
Net debt 3194.70M 5342.10M 6497.00M 3453.80M 4711.90M
Short term debt - 999.10M 7426.00M 1495.80M -
Short long term debt - 999.10M - 1495.80M -
Short long term debt total 6614.00M 7603.50M 7828.20M 6367.50M 5936.50M
Other stockholder equity -2913.30000M -2845.40000M -2991.30000M -2981.20000M -2985.10000M
Property plant equipment 3298.60M 3416.40M 3411.50M 3247.30M 3601.20M
Total current assets 9791.20M 7856.50M 6887.10M 8381.80M 7640.90M
Long term investments 2234.90M 892.00M 772.10M 1408.10M 1375.90M
Net tangible assets 5798.80M 2913.80M 1853.90M 4058.00M 4213.20M
Short term investments 1473.50M 1541.10M 1278.90M 1562.20M 2313.40M
Net receivables 2136.40M 1549.40M 1913.80M 1880.50M 1958.50M
Long term debt 6281.00M 6274.00M 7426.20M 4459.00M 5936.50M
Inventory 1344.40M 1351.50M 1068.60M 804.20M 929.90M
Accounts payable 491.50M 589.20M 454.90M 530.80M 370.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity -9.50000M 63.50M -14.20000M -4.10000M -8.00000M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -164.90000M -106.70000M -299.00000M -135.20000M -240.40000M
Additional paid in capital - - - - -
Common stock total equity 0.10M 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity 16466.50M 13911.70M 13976.30M 16455.40M 16257.00M
Treasury stock -2977.10000M -2977.10000M -2977.10000M -2977.10000M -2977.10000M
Accumulated amortization - - - - -
Non currrent assets other 1529.20M 1941.00M -1369.50000M -3232.10000M -2153.90000M
Deferred long term asset charges - - - 3232.10M 2153.90M
Non current assets total 14762.90M 16020.80M 17731.80M 18852.50M 17648.00M
Capital lease obligations 333.00M 330.40M 402.00M 412.70M -
Long term debt total 6281.00M 6274.00M 7426.20M 4459.00M 5936.50M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1576.60M -309.80000M -29.90000M 1233.70M 339.40M
Change to liabilities -347.70000M -9.10000M -50.40000M 213.00M 770.90M
Total cashflows from investing activities 1576.60M -563.70000M -608.60000M 470.50M -2046.30000M
Net borrowings -1002.20000M -170.00000M 1467.40M 1467.40M -3.20000M
Total cash from financing activities -1747.30000M -2086.20000M -5272.70000M -5860.40000M -4472.00000M
Change to operating activities -224.40000M -238.70000M 193.80M 133.60M 335.80M
Net income 2961.60M 1727.60M 4060.50M 5888.50M 4474.00M
Change in cash 1157.90M 930.20M -1582.50000M 1689.10M -349.20000M
Begin period cash flow 2261.40M 1331.20M 2913.70M 1224.60M 1573.80M
End period cash flow 3419.30M 2261.40M 1331.20M 2913.70M 1224.60M
Total cash from operating activities 1384.30M 3639.90M 4229.80M 7078.60M 6187.70M
Issuance of capital stock - - - - -
Depreciation 518.40M 487.70M 457.20M 680.60M 1016.60M
Other cashflows from investing activities 604.10M 4.20M -153.90000M -248.70000M -1615.10000M
Dividends paid - 0.70M 4.60M - 36.40M
Change to inventory -320.20000M -462.40000M -316.30000M -19.20000M -52.10000M
Change to account receivables -203.40000M 324.80M 2.80M 68.80M -205.20000M
Sale purchase of stock -750.00000M -1800.00000M -6679.10000M -5868.30000M -4352.60000M
Other cashflows from financing activities 6.80M -114.80000M 2915.60M 7.90M -114.10000M
Change to netincome -1471.30000M 743.30M 673.60M 254.90M 296.90M
Capital expenditures 243.20M 294.90M 551.80M 669.50M 886.10M
Change receivables -203.40000M 324.80M 2.80M 68.80M -205.20000M
Cash flows other operating 246.90M 828.00M -597.60000M -8.00000M -113.40000M
Exchange rate changes - - - 0.40M -18.60000M
Cash and cash equivalents changes 1213.60M 990.00M -1651.50000M 1689.10M -349.20000M
Change in working capital -890.30000M -145.50000M -187.20000M 199.30M 400.20M
Stock based compensation 254.10M 238.60M 198.30M 182.30M 157.50M
Other non cash items -1290.90000M 1758.30M -448.00000M 60.80M 31.10M
Free cash flow 1141.10M 3345.00M 3678.00M 6409.10M 5301.60M

Fundamentals

  • Previous Close 218.92
  • Market Cap37379.34M
  • Volume757004
  • P/E Ratio25.64
  • Dividend Yield3.71%
  • EBITDA2536.60M
  • Revenue TTM9993.30M
  • Revenue Per Share TTM69.17
  • Gross Profit TTM 7895.10M
  • Diluted EPS TTM10.06

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIIB
Biogen Inc		 0.80 0.37% 219.72 25.64 15.13 3.60 2.48 4.14 17.90
LLY
Eli Lilly and Company		 -2.77 0.36% 775.00 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson		 0.23 0.15% 148.95 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 -2.1 1.29% 160.45 42.38 13.68 4.88 22.14 5.72 31.93
MRK
Merck & Company Inc		 -0.83 0.64% 129.55 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc

225 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Michael R. McDonnell CPA Exec. VP & CFO 1964
Ms. Susan H. Alexander Esq. Exec. VP, Chief Legal Officer & Sec. 1957
Mr. Christopher A. Viehbacher Pres, CEO & Director 1960
Ms. Robin C. Kramer Sr. VP & Chief Accounting Officer 1966
Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology NA
Mr. Michael Hencke Head of Investor Relations NA
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corp. Affairs NA
Dr. Ginger Gregory Exec. VP & Chief HR Officer 1968
Dr. Anabella Villalobos Ph.D. Head of Biotherapeutics & Medicinal Sciences 1959
Dr. Sanjay Jariwala Sr. VP of Worldwide Medical NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).